


Product Name : ORIC-944
Cat. No. : PC-22119
CAS No. : 2369769-29-7
Molecular Formula : C₂₆H₂₅FN₆O
Molecular Weight : 456.53
Target : Histone Methyltransferase (HMTase)
Solubility : 10 mM in DMSO



CAS: 2369769-29-7

Biological Activity

ORIC-944 (Rinzimetostat) is a potent, selective, allosteric and orally bioavailable **PRC2** inhibitor with **EED** binding EC₅₀ of 106 pM and biochemical PRC2 EC₅₀ of 16.7 nM.

ORIC-944 exhibits H3K27me₃ IC₅₀ of 26.6 nM in cell based H3K27me₃ assay performed in Pfeiffer cells in ELISA format.

ORIC-944 demonstrated single agent tumor growth inhibition in a spectrum of in vivo prostate cancer models, including AR-positive, AR-mutant, ARv7, ARPI-responsive and ARPI-resistant models.

ORIC-944 showed synergy in multiple prostate cancer cells when combined with androgen receptor pathway inhibitors (ARPI).

ORIC-944 inhibits tumor growth and decreases H3K27me₃ in prostate cancer xenografts, resulting in increased expression of known PRC2 methylation target genes.

References

Anneleen Daemen, et al. **Cancer Res** (2024) 84 (6_Supplement): 6586.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com